NGN. V. Gegeliya

N. V. Gegeliya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N. V. Gegeliya has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Myoepithelial carcinoma of bones and soft tissues in children: a single-center experience

    by Valeriya O. Shestyuk, E. I. Konopleva, I. V. Sidorov, K. Yu. Sinichenkova, A. S. Sharlai, A. V. Panferova, N. V. Gegeliya, R. Kh. Abasov, M. M. Strozhenkov, A. Yu. Artemov, et al.

    Introduction. Myoepithelial сarcinoma (MC) is a rare and highly malignant neoplasm. Primary soft tissue involvement predominates in pediatrics (MCST), while MC of bones has been described in isolated cases. The rarity of MC combined with its polymorphic phenotype significantly challenge diagnosis and determine the absence of standardized treatment approaches. Aim: to analyze the specifics of diagnosis and treatment of children with MC at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation. Material and methods. The study included 7 patients aged 1.3 to 14.2 years who were diagnosed with MC and registered between 2017 and 2024. Results and discussion. MC of soft tissue was diagnosed in 6/7 cases and MC of bones in 1/7. Five out of seven cases were localized, while 2/7 cases presented with distant metastases. In 3 cases a deletion of the SMARCB1 gene was identified, and in 1 case deletion of the EWSR1 gene was detected. Surgical resection proved to be the cornerstone of the treatment program for patients with MC (R0 – n = 3; R1 – n = 3; R2 – n = 1). 5 patients underwent external beam radiation therapy. In 4 cases of localized MC, courses of chemotherapy (ICpE) were administered as an adjuvant. In 1 case courses of ICpE and IVE were given perioperatively. In the first case of metastatic MCST courses of ICpE/IVE were also administered; and in the second case a combination of AP + vinorelbine was used. Follow-up outcomes: 4/7 patients are alive with 3/4 alive without events. Conclusion. The results of our study mostly align with international experience and emphasize the significance of local control, as well as the leading role of a multidisciplinary approach and multicenter data sharing in improving the diagnostic and therapeutic outcomes for patients with MC.

  • Open Access

    Clinical, morphological and molecular genetic characteristics in patients with bilateral kidney tumors

    by G. B. Sagoyan, A. M. Mitrofanova, A. M. Suleymanova, V. V. Semenova, M. V. Rubanskaya, N. V. Gegeliya, P. A. Kerimov, S. R. Varfolomeeva

    Introduction. Bilateral kidney tumors (BKT) in patients with nephroblastoma is a relatively rare clinical situation and a more complex treatment challenge. The aim of the study was to evaluate the clinical, morphological, and molecular genetic characteristics of patients with BKT. Materials and methods. A retrospective analysis was conducted of 30 patients aged 2.4 to 56.2 months with histologically confirmed nephroblastoma/nephroblastomatosis treated at the Blokhin National Medical Research Center of Oncology from September 1, 2019, to June 1, 2024. Clinical and morphological features, molecular genetic characteristics, the presence of predisposing conditions, and the extent of surgical intervention were examined. Results. The median age at diagnosis in patients with and without tumor predisposition syndrome (PS) was 25 months (range, 2.4–56.2 months) and 30 months (range, 12.6–51.1 months), respectively. The female:male ratio was 1.5:1. In 23/29 (79,3%) patients with BKT, based on molecular genetic studies, germinal mutations in genes and epigenetic disorders were detected (in most cases, mutations in the WT1 and TRIM28 genes were detected and the Beckwith–Wiedemann syndrome spectrum was diagnosed). A statistically significant effect of the histological variant of nephroblastoma and PS was observed: WT1 patients had predominantly stromal histology, TRIM28 patients had epithelial histology, and patients with Beckwith–Wiedemann syndrome spectrum had predominantly regressive nephroblastoma (p 0.001). In 70% of cases, the main clinical sign indicating a renal tumor was abdominal enlargement and/or the presence of a tumor in the abdominal cavity. Stage V disease was diagnosed in 80% of children, and stage IV (metastatic lung disease) in 20%. After 6 weeks of VA therapy, 12/30 (40%) patients required additional courses of polychemotherapy using the VA and Carbo/Eto regimens according to the UMBRELLA SIOP-RTSG 2016 protocol. In 2/12 (16.7%) patients, negative dynamics were observed with tumor growth during specialized treatment; both patients had bilateral stromal nephroblastoma. Surgical treatment in most cases involved bilateral nephron-sparing surgery (22/30; 73.3%), and only 6 cases were microscopically classified as R1 resections. The local stage at which the patient subsequently received therapy was stage I in most cases (60%). Three-year overall survival and event-free survival were 93.3% and 87.8%, respectively. Four events were recorded: one local recurrence and three deaths (one due to disease progression, one due to infectious complications, and one due to early postoperative pulmonary embolism). Conclusions. BKT is a rare condition requiring a multidisciplinary approach. Additional courses of chemotherapy according to the UMBRELLA SIOP-RTSG 2016 protocol improve the response to therapy in most cases, reducing tumor size and increasing the likelihood of organ-preserving surgery. In cases of lack of response to chemotherapy or disease progression, surgical treatment is considered. Surgical treatment should be performed in specialized centers. Genetic counseling is necessary to exclude BKT. There is a correlation between the histological variant of nephroblastoma and PS.

  • Open Access

    Treatment outcomes in standard-risk medulloblastoma patients: the role of molecular genetic stratifications

    by Andrey N. Flegontov, A. E. Druy, A. V. Protsvetkina, M. A. Zaytseva, N. V. Gegeliya, V. S. Petrova, M. A. Senchenko, A. V. Tarakanova, A. V. Sanakoeva, A. V. Artyomov, et al.

    Introduction. Medulloblastoma (MB) is a clinically and biologically heterogeneous tumor of the central nervous system (CNS); however, current risk stratification criteria rely primarily on its clinical and morphological features. The aim of the study was to assess molecular and genetic characteristics of MB in standard risk group patients and analyze their impact on the clinical course of the disease and long-term treatment outcomes. Materials and methods. This retrospective study included 137 patients with standard-risk MB according to the criteria in the HIT-MED 2020. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. All the patients underwent molecular subgrouping (WNT, SHH, Group 3, or Group 4). Overall survival (OS), event-free survival (EFS), and relapse characteristics were assessed in relation to molecular subgroup, craniospinal irradiation (CSI) dose, and time to the start of radiotherapy. Results. Five-year OS and EFS rates for the entire cohort were 84% and 74%, respectively. The most favorable outcomes were observed in the WNT subgroup (OS 93%, EFS 86%); however, recurrences occurred in 14.6% of the patients, exclusively among those who received a CSI dose of 23.4 Gy. In the SHH subgroup, the recurrence rate was 39.1% and was associated with the presence of TP53 mutations. CSI dose escalation of did not improve survival in this subgroup. Patients in Group 3 had the poorest prognosis, with a high rate of early metastatic relapses, particularly among those treated with a CSI dose of 23.4 Gy. Patients in Group 4 had intermediate survival and a moderate recurrence rate (22%). Neither CSI dose nor the time to the start of radiation therapy had a significant impact on survival in the entire cohort. Conclusion. Molecular subgroups are an important prognostic factor even in patients with favorable clinical and morphological profiles. Our findings support the need to integrate molecular stratification into routine clinical practice and to be careful when considering de-escalation or intensification of treatment strategies in the standard-risk group.

  • Open Access

    Aspects of molecular diagnostics and clinical characteristics of children and adolescents with CIC-rearranged sarcoma

    by Ksenia Yu. Sinichenkova, A. V. Panferova, R. Kh. Abasov, N. V. Gegeliya, I. V. Sidorov, A. S. Sharlay, D. M. Konovalov, D. V. Litvinov, G. A. Novichkova, A. E. Druy

    Introduction. CIC-rearranged sarcoma is the most aggressive tumor of all undifferentiated small round cell sarcomas (USRCSs) of bone and soft tissue, characterized by a high incidence of distant metastases and disease progression during first-line treatment. In this article, we describe clinical, biological and molecular characteristics and tools for quick and precise molecular diagnosis. Aim – to evaluate the molecular features of sarcoma with CIC gene rearrangement and to investigate the clinical and prognostic characteristics in children with CIC-rearranged sarcoma. Materials and methods. We analyzed the clinical and molecular characteristics of 20 patients with the following initial morphological diagnoses: USRCS, undifferentiated spindle cell sarcoma, CIC-rearranged sarcoma. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Results. Fourteen out of 20 patients were diagnosed with CIC-rearranged sarcoma using molecular diagnostic assays. In 12 out of these 14 patients direct molecular markers were identified using RNA sequencing, in 2 patients the diagnosis was confirmed using NanoString’s molecular barcoding technology. Survival analysis was performed for 12 out of 14 patients; the 3-year overall and disease-free survival rates were 34.4 ± 16.0% and 23.8 ± 14.6%, respectively. Conclusion. Patients suspected of CIC-rearranged sarcoma always require comprehensive molecular diagnostic testing to avoid misdiagnosis. CIC-rearranged sarcoma has the most aggressive clinical course of all USRCSs, is characterized by early disease progression and requires a more intensive treatment approach.

  • Open Access

    Molecular and Clinical Characteristics of Sarcomas with BCOR Genetic Alteration in Children and Adolescents

    by Ксения Юрьевна Синиченкова, Агнеса Владимировна Панферова, Руслан Худавердиевич Абасов, Нина Валерьевна Гегелия, Илья Владимирович Сидоров, Анастасия Сергеевна Шарлай, Дмитрий Михайлович Коновалов, Дмитрий Витальевич Литвинов, Галина Анатольевна Новичкова, Александр Евгеньевич Друй

    Введение. Саркома с аберрацией гена BCOR представляет собой относительно недавно охарактеризованную группу опухолей, характеризующуюся аберрациями гена BCOR, приводящих к его онкогенной активации, в результате чего они имеют разнообразное клиническое поведение, отличное от саркомы Юинга (СЮ), с которой данные опухоли имеют определенное морфологическое сходство. Морфологический диагноз в подавляющем большинстве случаев оказывается верен, однако для его подтверждения порой приходится прибегать к многообразию методик молекулярной диагностики для определения прямых или суррогатных диагностических маркеров. Материалы и методы. В исследование вошло 23 пациента с молекулярно-подтвержденным диагнозом саркомы с аберрацией гена BCOR при помощи ОТ-ПЦР, секвенирования РНК или метода цифрового баркодирования РНК Nanostring. Всем пациентам проведена оценка клинических данных и показателей общей и бессобытийной выживаемости в зависимости от проведенного лечения методом Каплана — Майера. Результаты. У 22 (96 %) пациентов из 23 входящим морфологическим диагнозом являлась саркома с аберрацией гена BCOR, у одного (4 %) пациента — недифференцированная мелкокруглоклеточная саркома (НМКкС). Морфологический диагноз был подтвержден в 17 из 23 случаев методом ОТ-ПЦР, в двух случаях — с пограничным качеством выделенной РНК методом цифрового баркодирования РНК Nanostring, у четверых — методом высокопроизводительного секвенирования с обнаружением более редких аберраций — BCOR ITD (ex15), BCOR::MAML3 (ex15::ex2) и YWHAE::NUTM2B (ex5::ex2). Медиана возраста на момент заболевания составила 10,5 (0,25–16,4) года. Локализованная форма была диагностирована в 17 (74 %) случаях, в 6 (26 %) определялись отдаленные метастазы. 13 (57 %) пациентов получали лечение в соответствии с протоколами Euro Ewing-2008 и 2012, 10 (43 %) — CWS-2009. Рецидив развился у восьми человек (35 %), у шести из восьми — локальный, у двух — системный. Общая трехлетняя выживаемость среди 23 пациентов составила 96,0 ± 0,04 %, бессобытийная выживаемость — 66,8 ± 0,12 %. Выводы. Для пациентов с наиболее часто встречаемой перестройкой BCOR::CCNB3 характерны индолентное течение, тропность к костям осевого скелета и преобладание у лиц мужского пола. При сравнении бессобытийной выживаемости в зависимости от использования юинг-ориентированного протокола лечения или протокола лечения для мягкотканых сарком достоверной разницы не получено.

  • Open Access

    Molecular genetic features of neuroblastoma in adolescent

    by N. A. Andreeva, T. V. Shamanskaya, D. Yu. Kachanov, R. Kh. Abasov, N. V. Gegeliya, A. E. Druy

    Aim. To determin the clinical and biological features of neuroblastoma in patients over 10 years old. Materials and methods. Patients with a histologically verified diagnosis of neuroblastoma / ganglioneuroblastoma established over the age of 10 years were retrospectively selected. Molecular genetic tests included fluorescence in situ hybridization (FISH), multiplex ligation-dependent amplification (MLPA) and targeted next generation sequencing of tumor-derived DNA. The described cohort included 11 adolescents with histologically verified neuroblastoma / ganglioneuroblastoma with a median age of 160 months (124–173 months) at diagnosis and 1 patient aged 41 years (clinical data is missing). All adolescents were treated according to the neuroblastoma treatment protocol NB-2004. The median follow-up time for patients (n = 11) was 32 months (8–68 months). Results. MYCN gene amplification was detected by FISH in 17 %; deletion of 1p and 11q – in 20 and 22.2 % of cases, respectively. Deletions of 1p and 3p (80 % cases each), 11q (67 % cases), 4p (56 % cases), and gain 17q (62.5 % cases) were frequently detected in tumors (n = 9) by MLPA. ATRX gene aberrations was found in 91.6 % (11 / 12). In the most cases (10 / 11; 90 %), ATRX gene deletions of varying length were detected. Missense substitutions p.V1678F, p.N2125I and nonsense mutation p.S213* were detected in 3 / 11 (27.3 %) patients. Moreover, in 2 patients, oncogenic nucleotide substitutions were identified in combination with ATRX gene deletion entire and monosomy X. Oncogenic genetic variants in components of the RAS-RAF-MEK (BRAF, NRAS, ALK) and p53 (ATM, TP53) pathways were detected in 58 % (7 / 12) of cases. No adverse events were observed when ALK inhibitors were added to first-line therapy in neuroblastomas harboring activating ALK mutations. Conclusion. The clinical aggressiveness of adolescent / adult NB may be explained by the replicative immortalization of cells through alternative lengthening of telomeres, which is highlighted by ATRX aberrations. Special therapeutic recommendations should be elaborated for the treatment of patients in this age group, where special attention should be paid to the use of molecularly targeted therapy.

  • «Malignant stroma?» Alternative localization of classical genetic aberrations in neuroblastoma

    by A.S. Sharlai, N.V. Gegeliya, A.E. Druy, D.M. Konovalov

    Нейробластома (НБ) — это злокачественное новообразование, возникающее из примитивных клеток симпатической нервной системы. На основании клинических и молекулярно-генетических характеристик (статус генов MYCN, ALK, регионов 1p и 11q) все НБ стратифицируют на группы риска. Поскольку гистологическое строение и клеточный состав НБ сильно варьируют, интерпретация результата генетических исследований может стать непростой задачей. В статье описано 2 наблюдения с классическими для НБ хромосомными аберрациями в стромальном компоненте опухоли.